Life360 Reports Record Q2 2025 Results
LIFELife360 delivered record results across multiple metrics, including MAUs, Subscription Revenue, and AMR. Raised full-year guidance for revenue and AEBITDA.
August 11, 2025Earnings
Read more →aTyr Pharma Gets FDA Fast Track Status For Systemic Sclerosis Candidate
LIFEThe U.S. Food and Drug Administration (FDA) has granted Fast Track designation for aTyr Pharma’s (NASDAQ: LIFE) lead therapeutic candidate, efzofitimod, for the treatment of systemic sclerosis (SSc)-associated, interstitial lung disease (ILD).
September 13, 2022
Read more →aTyr Pharma Receives FDA Fast Track Designation For Efzofitimod For Treatment Of Systemic Sclerosis-Associated Interstitial Lung Disease
LIFESeptember 13, 2022
Read more →